Literature DB >> 31612494

Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer.

Casey J Allen1, Timothy E Newhook1, Timothy J Vreeland1, Prajnan Das2, Bruce D Minsky2, Mariela Blum3, Shumei Song3, Jaffer Ajani3, Naruhiko Ikoma, Paul F Mansfield, Sinchita Roy-Chowdhuri4, Brian D Badgwell.   

Abstract

BACKGROUND: Guidelines for gastric and gastroesophageal (GE) cancer recommend staging laparoscopy (SL) with peritoneal cytology (PC). However, the reliability of PC is unknown. The primary purpose of this study was to determine the sensitivity of PC.
METHODS: We analyzed a prospectively maintained database of patients who underwent SL and PC for gastric and GE cancer. Test sensitivity of PC for detecting peritoneal disease was assessed. Survival analyses were used to examine the implication of PC.
RESULTS: There were 1186 patients that underwent SL and PC; 282 (24%) were found with carcinomatosis. PC was analyzed in 214 (76%) of these patients and 77 (36%) were found to have no malignant cells. In this setting, PC had a sensitivity of 64% for confirming peritoneal disease. Those with peritoneal disease had a poorer 5-year overall survival (5.8% vs 37.7%; P < .001). Those with positive PC without carcinomatosis had a similar survival to those with gross disease with and without cytological confirmation (both P > .05).
CONCLUSIONS: PC has limited sensitivity for detecting peritoneal disease. Positive PC alone carries a similar poor survival as in patients with gross carcinomatosis. Improvements in the identification of microscopic disease in peritoneal washings are needed.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  carcinomatosis; gastric cancer; peritoneal washings; staging laparoscopy; survival

Mesh:

Year:  2019        PMID: 31612494     DOI: 10.1002/jso.25729

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

Review 2.  Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease.

Authors:  Hamza Khan; Fabian M Johnston
Journal:  J Surg Oncol       Date:  2022-06       Impact factor: 2.885

3.  Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases.

Authors:  Huayuan Liang; Zhiwei Li; Zhicheng Huang; Chaorui Wu; Yaopeng Qiu; Yanrui Liang; Xinhua Chen; Fengping Li; Zhou Xu; Guoxin Li; Hao Liu; Liying Zhao
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

4.  Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma.

Authors:  Casey J Allen; Alisa N Blumenthaler; Prajnan Das; Bruce D Minsky; Mariela Blum; Sinchita Roy-Chowdhuri; Jaffer A Ajani; Naruhiko Ikoma; Paul F Mansfield; Brian D Badgwell
Journal:  World J Surg Oncol       Date:  2020-02-17       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.